Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday

Pfizer (NYSE:PFE) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Pfizer to post earnings of $0.68 per share and revenue of $14.3994 billion for the quarter. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.92 earnings per share. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Stock Performance

PFE stock opened at $25.39 on Tuesday. The firm has a 50 day moving average of $25.10 and a two-hundred day moving average of $26.17. Pfizer has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a market capitalization of $144.74 billion, a price-to-earnings ratio of 19.39 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is presently 131.30%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth $32,000. IFC & Insurance Marketing Inc. bought a new stake in Pfizer during the fourth quarter valued at about $34,000. Birchwood Financial Partners Inc. bought a new stake in Pfizer during the fourth quarter valued at about $38,000. WFA of San Diego LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $40,000. Finally, Atlas Capital Advisors Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $41,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s cancer and obesity pipeline is being presented as a potential “reset” for the company. Investors are watching whether new treatments and business-development efforts can replace revenue lost from older products and COVID products. Can Pfizer Turn Its Cancer and Obesity Reset Into a New Chapter?
• Positive Sentiment: The FDA’s Priority Review of TALZENNA in combination with XTANDI for an earlier form of metastatic prostate cancer could expand Pfizer’s precision-oncology franchise. A broader eligible patient population may support longer-term growth for the cancer portfolio. Did FDA Priority Review of TALZENNA Plus XTANDI Shift Pfizer’s Investment Narrative?
• Positive Sentiment: Market commentary highlights Pfizer’s relatively low valuation as a reason value-oriented investors are revisiting the shares. Pfizer recently reported quarterly revenue and earnings above analyst expectations, while full-year 2026 guidance remains intact. Pfizer Edges Up as Low-Multiple Pharma Draws Value Notice
• Neutral Sentiment: Political attention around the CDC’s reported $1.24 billion Pfizer COVID-19 vaccine contracts keeps the company in the public-policy spotlight. The contracts could provide commercial support, but renewed debate may increase reputational and regulatory uncertainty. GOP Congressman Questions Silence Over Pfizer Vaccine Contracts
• Negative Sentiment: Analysts continue to warn that Pfizer faces a real patent cliff, with future sales potentially pressured by generic competition. The low valuation may reflect these risks, meaning the stock’s recovery depends on successful pipeline launches and replacement revenue. Pfizer: Calling the Bottom

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Morgan Stanley raised their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.